| P50 | author | Marie Jalovecká | Q56798590 |
| | Anthony J. O'Donoghue | Q56916758 |
| | Daniel Sojka | Q95093330 |
| P2093 | author name string | Lars Eckmann | |
| | Ondrej Hajdusek | |
| | David Hartmann | |
| | Yukiko Miyamoto | |
| P2860 | cites work | Large-scale phylogenomic analyses reveal that two enigmatic protist lineages, telonemia and centroheliozoa, are related to photosynthetic chromalveolates | Q23380247 |
| | Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance | Q24681513 |
| | Babesiosis | Q26829108 |
| | From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes | Q26864557 |
| | Natural history of Zoonotic Babesia: Role of wildlife reservoirs | Q27002385 |
| | Immunoproteasomes: structure, function, and antigen presentation | Q27024527 |
| | Molecular architecture and assembly of the eukaryotic proteasome | Q27693890 |
| | Human babesiosis | Q28269239 |
| | Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance | Q28546636 |
| | Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness | Q28817181 |
| | Mitochondrial Genome Sequences and Structures Aid in the Resolution of Piroplasmida phylogeny | Q28821648 |
| | The 26S proteasome: a molecular machine designed for controlled proteolysis | Q29619692 |
| | First documented case of human babesiosis in Sweden | Q33354627 |
| | Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy | Q33357936 |
| | United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy | Q33371230 |
| | A common red algal origin of the apicomplexan, dinoflagellate, and heterokont plastids | Q33934728 |
| | Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. | Q53233409 |
| | First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen | Q56773866 |
| | Isolation of Babesia divergens from carrier cattle blood using in vitro culture | Q79964336 |
| | Assembly, structure, and function of the 26S proteasome. | Q33988314 |
| | Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity | Q34473136 |
| | Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti | Q34491565 |
| | Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome | Q34501396 |
| | Babesiosis: similar to malaria but different | Q34571537 |
| | A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo | Q34582794 |
| | Babesia: an emerging infectious threat in transfusion medicine | Q34819404 |
| | The proteasome: a suitable antineoplastic target | Q35762448 |
| | Babesiosis of cattle. | Q36153268 |
| | Suppression of BRCA1 sensitizes cells to proteasome inhibitors | Q36292025 |
| | Human Babesiosis: Pathogens, Prevalence, Diagnosis and Treatment | Q36292294 |
| | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma | Q36384889 |
| | Chemotherapy against babesiosis | Q36407682 |
| | Structure- and function-based design of Plasmodium-selective proteasome inhibitors | Q36584903 |
| | Acquisition of exogenous haem is essential for tick reproduction | Q36768068 |
| | Limitations of SLLVY-AMC in calpain and proteasome measurements | Q37218606 |
| | Proteasome inhibitors: an expanding army attacking a unique target | Q37979388 |
| | Babesia: a world emerging. | Q38032685 |
| | Bovine babesiosis in the 21st century: advances in biology and functional genomics | Q38052243 |
| | Structural biology of the proteasome | Q38081952 |
| | Human babesiosis in Europe: what clinicians need to know | Q38150686 |
| | Phylogeny and evolution of apicoplasts and apicomplexan parasites | Q38275826 |
| | The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria. | Q38861425 |
| | Targeting proteasomes in infectious organisms to combat disease | Q39103077 |
| | Severe human Babesia divergens infection in Norway | Q39287339 |
| | Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events | Q39583670 |
| | Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity | Q40139788 |
| | Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti infection associated with Rituximab and Chronic Lymphocytic Leukemia. | Q40199750 |
| | Babesiosis in splenectomized adults. Review of 22 reported cases | Q40211486 |
| | Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea. | Q40448654 |
| | A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse | Q40559129 |
| | Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin | Q40669200 |
| | Fatal babesiosis in man, Finland, 2004. | Q42053973 |
| | Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer | Q43160211 |
| | Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection | Q43202835 |
| | Evaluation of the in vitro growth-inhibitory effect of epoxomicin on Babesia parasites | Q43246722 |
| | Babesiosis and infection with human immunodeficiency virus (HIV) | Q44624807 |
| | Babesiosis and HIV. | Q44786718 |
| | Expressed sequence tag (EST) analysis of the erythrocytic stages of Babesia bovis | Q44890427 |
| | A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. | Q45969598 |
| | Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome | Q46119731 |
| | Persistent and relapsing babesiosis in immunocompromised patients | Q46817889 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| | parasitology | Q180502 |
| P304 | page(s) | 394-402 | |
| P577 | publication date | 2018-08-07 | |
| P1433 | published in | International Journal for Parasitology: Drugs and Drug Resistance | Q20181953 |
| P1476 | title | Validation of Babesia proteasome as a drug target | |
| P478 | volume | 8 | |